|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petignat P and Roy M: Diagnosis and
management of cervical cancer. BMJ. 335:765–768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moreau ME, Garbacki N, Molinaro G, Brown
NJ, Marceau F and Adam A: The kallikrein-kinin system: Current and
future pharmacological targets. J Pharmacol Sci. 99:6–38. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maeda H, Wu J, Okamoto T, Maruo K and
Akaike T: Kallikrein-kinin in infection and cancer.
Immunopharmacology. 43:115–128. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Searovic P, Alonso M, Oses C,
Pereira-Flores K, Velarde V and Saez CG: Effect of tamoxifen and
retinoic acid on bradykinin induced proliferation in MCF-7 cells. J
Cell Biochem. 106:473–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu J, Akaike T, Hayashida K, Okamoto T,
Okuyama A and Maeda H: Enhanced vascular permeability in solid
tumor involving peroxynitrite and matrix metalloproteinases. Jpn J
Cancer Res. 92:439–451. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang WH, Chang JT, Hsu SF, Li TM, Cho DY,
Huang CY, Fong YC and Tang CH: Bradykinin enhances cell migration
in human chondrosarcoma cells through BK receptor signaling
pathways. J Cell Biochem. 109:82–92. 2010.PubMed/NCBI
|
|
8
|
Menke JG, Borkowski JA, Bierilo KK,
MacNeil T, Derrick AW, Schneck KA, Ransom RW, Strader CD, Linemeyer
DL and Hess JF: Expression cloning of a human B1 bradykinin
receptor. J Biol Chem. 269:21583–21586. 1994.PubMed/NCBI
|
|
9
|
Wang G, Ye Y, Zhang X and Song J:
Bradykinin stimulates IL-6 production and cell invasion in
colorectal cancer cells. Oncol Rep. 32:1709–1714. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vassou D, Notas G, Hatzoglou A, Castanas E
and Kampa M: Opioids increase bladder cancer cell migration via
bradykinin B2 receptors. Int J Oncol. 39:697–707. 2011.PubMed/NCBI
|
|
11
|
Yu HS, Wang SW, Chang AC, Tai HC, Yeh HI,
Lin YM and Tang CH: Bradykinin promotes vascular endothelial growth
factor expression and increases angiogenesis in human prostate
cancer cells. Biochem Pharmacol. 87:243–253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou Y, Wang W, Wei R, Jiang G, Li F, Chen
X, Wang X, Long S, Ma D and Xi L: Serum bradykinin levels as a
diagnostic marker in cervical cancer with a potential mechanism to
promote VEGF expression via BDKRB2. Int J Oncol. 55:131–141.
2019.PubMed/NCBI
|
|
13
|
Wang X, Crowe PJ, Goldstein D and Yang JL:
STAT3 inhibition, a novel approach to enhancing targeted therapy in
human cancers (Review). Int J Oncol. 41:1181–1191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yao S, Xu J, Zhao K, Song P, Yan Q, Fan W,
Li W and Lu C: Down-regulation of HPGD by miR-146b-3p promotes
cervical cancer cell proliferation, migration and
anchorage-independent growth through activation of STAT3 and AKT
pathways. Cell Death Dis. 9:10552018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saini U, Naidu S, ElNaggar AC, Bid HK,
Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy,
et al: Elevated STAT3 expression in ovarian cancer ascites promotes
invasion and metastasis: A potential therapeutic target. Oncogene.
36:168–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alvarez JV, Greulich H, Sellers WR,
Meyerson M and Frank DA: Signal transducer and activator of
transcription 3 is required for the oncogenic effects of
non-small-cell lung cancer-associated mutations of the epidermal
growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang S, Yang C, Yu F, Ding W, Hu Y, Cheng
F, Zhang F, Guan B, Wang X, Lu L and Rao J: Endoplasmic reticulum
resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma
metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway.
Cell Death Dis. 9:11052018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pradeep S, Huang J, Mora EM, Nick AM, Cho
MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, et al:
Erythropoietin stimulates tumor growth via EphB4. Cancer Cell.
28:610–622. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smith HA and Kang Y: The
metastasis-promoting roles of tumor-associated immune cells. J Mol
Med (Berl). 91:411–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Z, Tian Z, Cao K, Zhang B, Wen Q, Zhou
X, Yang W, Wang T, Shi H and Wang R: TSG101 promotes the
proliferation, migration and invasion of hepatocellular carcinoma
cells by regulating the PEG10. J Cell Mol Med. 23:70–82. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shishodia G, Shukla S, Srivastava Y,
Masaldan S, Mehta S, Bhambhani S, Sharma S, Mehrotra R, Das BC and
Bharti AC: Alterations in microRNAs miR-21 and let-7a correlate
with aberrant STAT3 signaling and downstream effects during
cervical carcinogenesis. Mol Cancer. 14:1162015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guha P, Gardell J, Darpolor J, Cunetta M,
Lima M, Miller G, Espat NJ, Junghans RP and Katz SC: STAT3
inhibition induces Bax-dependent apoptosis in liver tumor
myeloid-derived suppressor cells. Oncogene. 38:533–548. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang J, Jia J, Zhao L, Li X, Xie Q, Chen
X, Wang J and Lu F: Down-regulation of microRNA-9 leads to
activation of IL-6/Jak/STAT3 pathway through directly targeting
IL-6 in HeLa cell. Mol Carcinog. 55:732–742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao H, Wang W, Zhao Q, Hu G, Deng K and
Liu Y: BCL3 exerts an oncogenic function by regulating STAT3 in
human cervical cancer. Onco Targets Ther. 9:6619–6629. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
da Costa PL, Sirois P, Tannock IF and
Chammas R: The role of kinin receptors in cancer and therapeutic
opportunities. Cancer Lett. 345:27–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang G, Sun J, Liu G, Fu Y and Zhang X:
Bradykinin promotes cell proliferation, migration, invasion, and
tumor growth of gastric cancer through ERK signaling pathway. J
Cell Biochem. 118:4444–4453. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sabatini F, Luppi F, Petecchia L, Stefano
AD, Longo AM, Eva A, Vanni C, Hiemstra PS, Sterk PJ, Sorbello V, et
al: Bradykinin-induced asthmatic fibroblast/myofibroblast
activities via bradykinin B2 receptor and different MAPK pathways.
Eur J Pharmacol. 710:100–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Morikawa T, Baba Y, Yamauchi M, Kuchiba A,
Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS and
Ogino S: STAT3 expression, molecular features, inflammation
patterns, and prognosis in a database of 724 colorectal cancers.
Clin Cancer Res. 17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yin W, Cheepala S, Roberts JN, Syson-Chan
K, DiGiovanni J and Clifford JL: Active Stat3 is required for
survival of human squamous cell carcinoma cells in serum-free
conditions. Mol Cancer. 5:152006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wong AL, Soo RA, Tan DS, Lee SC, Lim JS,
Marban PC, Kong LR, Lee YJ, Wang LZ, Thuya WL, et al: Phase I and
biomarker study of OPB-51602, a novel signal transducer and
activator of transcription (STAT) 3 inhibitor, in patients with
refractory solid malignancies. Ann Oncol. 26:998–1005. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murakami T, Takigawa N, Ninomiya T, Ochi
N, Yasugi M, Honda Y, Kubo T, Ichihara E, Hotta K, Tanimoto M and
Kiura K: Effect of AZD1480 in an epidermal growth factor
receptor-driven lung cancer model. Lung Cancer. 83:30–36. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stewart JM: Bradykinin antagonists as
anti-cancer agents. Curr Pharm Des. 9:2036–2042. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Avdieiev S, Gera L, Havrylyuk D, Hodges
RS, Lesyk R, Ribrag V, Vassetzky Y and Kavsan V: Bradykinin
antagonists and thiazolidinone derivatives as new potential
anti-cancer compounds. Bioorg Med Chem. 22:3815–3823. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stewart JM, Gera L, Chan DC, Bunn PJ Jr,
York EJ, Simkeviciene V and Helfrich B: Bradykinin-related
compounds as new drugs for cancer and inflammation. Can J Physiol
Pharmacol. 80:275–280. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Monk BJ, Sill MW, Burger RA, Gray HJ,
Buekers TE and Roman LD: Phase II trial of bevacizumab in the
treatment of persistent or recurrent squamous cell carcinoma of the
cervix: A gynecologic oncology group study. J Clin Oncol.
27:1069–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
